Logo
x

Search category

Subscribe Now

Jacobio Pharma

Jacobio Pharma Reports Data from the P-II Study of Glecirasib for Treating Non-Small Cell Lung Cancer

Jacobio Pharma Reports Data from the P-II Study of Glecirasib for Treating Non-Small Cell Lung Cancer

  • May 1, 2024
Jacobio Pharma’s Glecirasib Receives the NMPA’s Breakthrough Therapy Designation for the Treatment of Pancreatic Cancer

Jacobio Pharma’s Glecirasib Receives the NMPA’s Breakthrough Therapy Designation for the Treatment of Pancreatic Cancer

  • August 8, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.